• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Australia Cannabis Market
    Australia Cannabis News
    Australia Cannabis Stocks
    • Australia Cannabis Market
    • Australia Cannabis News
    • Australia Cannabis Stocks

    Zelda Therapeutics Posts Quarterly Report, Provides Clinical Trial Update

    Danielle Edwards
    Oct. 31, 2019 06:10PM PST
    Australia Cannabis Investing
    Australia Cannabis Investing

    Zelda Therapeutics updated investors on its recent activities during the three months ended on September 30.

    Zelda Therapeutics (ASX:ZLD,OTCQB:ZLDAF) updated investors on its recent activities during the three months ended on September 30.

    As quoted in the press release:

    In July 2019, Zelda announced it had entered into a strategic partnership with Australia-based healthcare technology and services company Emerald Clinics Ltd (Emerald), which owns and operates
    an Australian network of dedicated medicinal cannabis clinics.

    Under the terms of the agreement Emerald will provide access to de-identified real-world longitudinal data collected from patients prescribed cannabis medicines for treatment of pain and/or insomnia.
    Data will include details regarding cannabis formulations and dosages prescribed to patients, their responses to treatment and the impact on usage of non-cannabis medicines such as opioids.

    This information will inform Zelda’s ongoing clinical trial strategy, which is focussed on developing new cannabis-based treatments to reduce opioid usage in patients with chronic pain as well as patients with insomnia and autism.

    Click here to read the full press release.

    The Conversation (0)

    Go Deeper

    AI Powered
    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies in 2025

    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Australia Cannabis Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×